Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis

• Published in: PLoS medicine Vol. 12; no. 2; p. e1001789
• Main Authors: Schwarz, Roland F, Ng, Charlotte K Y, Cooke, Susanna L, Newman, Scott, Temple, Jillian, Piskorz, Anna M, Gale, Davina, Sayal, Karen, Murtaza, Muhammed, Baldwin, Peter J, Rosenfeld, Nitzan, Earl, Helena M, Sala, Evis, Jimenez-Linan, Mercedes, Parkinson, Christine A, Markowetz, Florian, Brenton, James D
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01-02-2015; Public Library of Science (PLoS)
• Subjects: Aged; Algorithms; Alleles; Carcinoma, Ovarian Epithelial; Chemotherapy; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Epigenetic inheritance; Female; Genetic aspects; Genetic Variation; Humans; Identification and classification; Medical research; Middle Aged; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - genetics; Neoplasms, Glandular and Epithelial - mortality; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; Phylogeny; Platinum - therapeutic use; Studies; Womens health
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1001789

The major clinical challenge in the treatment of high-grade serous ovarian cancer (HGSOC) is the development of progressive resistance to platinum-based chemotherapy. The objective of this study was to determine whether intra-tumour genetic heterogeneity resulting from clonal evolution and the emergence of subclonal tumour populations in HGSOC was associated with the development of resistant disease.
Evolutionary inference and phylogenetic quantification of heterogeneity was performed using the MEDICC algorithm on high-resolution whole genome copy number profiles and selected genome-wide sequencing of 135 spatially and temporally separated samples from 14 patients with HGSOC who received platinum-based chemotherapy. Samples were obtained from the clinical CTCR-OV03/04 studies, and patients were enrolled between 20 July 2007 and 22 October 2009. Median follow-up of the cohort was 31 mo (interquartile range 22-46 mo), censored after 26 October 2013. Outcome measures were overall survival (OS) and progression-free survival (PFS). There were marked differences in the degree of clonal expansion (CE) between patients (median 0.74, interquartile range 0.66-1.15), and dichotimization by median CE showed worse survival in CE-high cases (PFS 12.7 versus 10.1 mo, p = 0.009; OS 42.6 versus 23.5 mo, p = 0.003). Bootstrap analysis with resampling showed that the 95% confidence intervals for the hazard ratios for PFS and OS in the CE-high group were greater than 1.0. These data support a relationship between heterogeneity and survival but do not precisely determine its effect size. Relapsed tissue was available for two patients in the CE-high group, and phylogenetic analysis showed that the prevalent clonal population at clinical recurrence arose from early divergence events. A subclonal population marked by a NF1 deletion showed a progressive increase in tumour allele fraction during chemotherapy.
This study demonstrates that quantitative measures of intra-tumour heterogeneity may have predictive value for survival after chemotherapy treatment in HGSOC. Subclonal tumour populations are present in pre-treatment biopsies in HGSOC and can undergo expansion during chemotherapy, causing clinical relapse.